Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6895-6902

  Onoyama, Takumi ^a   Koda, Masahiko ^a   Okamoto, Toshiaki ^a   Kishina, Manabu ^a   Matono, Tomomitsu ^a   Sugihara, Takaaki ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Dipeptidyl peptidase IV inhibitor; Fatty liver Shionogi ob ob mice; Hepatic fibrosis; Hepatic stellate cell; Non alcoholic steatohepatitis; Oxidative stress; Sitagliptin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; FATTY ACID SYNTHASE; GLUCOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1; SITAGLIPTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INFLAMMATORY CELL; KUPFFER CELL; LIPID METABOLISM; LIVER FIBROSIS; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; STELLATE CELL; WEIGHT REDUCTION; ANIMAL; COMPLICATION; DRUG EFFECTS; FIBROSIS; INFLAMMATION; LIVER; MOUSE MUTANT; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; APOPTOSIS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FIBROSIS; INFLAMMATION; LIVER; MALE; MICE; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SITAGLIPTIN PHOSPHATE;

EID: 84943608118     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4329     Document Type: Article

References (39)

1. Ding X, Saxena NK, Lin S, Gupta N and Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181, 2006.
2. Mentzel S, Dijkman HB, Van Son JP, Koene RA and Assmann KJ: Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 44: 445-461, 1996.
3. Heike M, Möbius U, Knuth A, Meuer S and Meyer zum Büschenfelde KH: Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol 74: 431-434, 1988.
4. Gorrell MD, Gysbers V and McCaughan GW: CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54: 249-264, 2001.
5. Dinjens WN, ten Kate J, Wijnen JT, van der Linden EP, Beek CJ, Lenders MH, Khan PM and Bosman FT: Distribution of adenosine deaminase-complexing protein in murine tissues. J Biol Chem 264: 19215-19220, 1989.
6. Brubaker PL and Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: The glucagon, GIP, GLP-1 and GLP-2 receptors. Receptors Channels 8: 179-188, 2002.
7. Reinehr T, Roth CL, Enriori PJ and Masur K: Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: Relationships to peptide YY, pancreatic peptide and insulin sensitivity. J Pediatr Endocrinol Metab 23: 101-108, 2010.
8. Yamabe T, Takakura K, Sugie K, Kitaoka Y, Takeda S, Okubo Y, Teshigawara K, Yodoi J and Hori T: Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 91: 151-158, 1997.
9. Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH and Morimoto C: Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 13: 2299-2310, 2008.
10. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, et al: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100: 6825-6830, 2003.
11. Itou M, Kawaguchi T, Taniguchi E and Sata M: Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol 19: 2298-2306, 2013.
12. Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K and Takayanagi R: Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 5: 729-733, 2012.
13. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E and Tatar G: Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 6: 242-250, 2007.
14. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R and Fishman S: Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54: 1214-1223, 2011.
15. Soga M, Kishimoto Y, Kawaguchi J, Nakai Y, Kawamura Y, Inagaki S, Katoh K, Oohara T, Makino S and Oshima I: The FLS mouse: A new inbred strain with spontaneous fatty liver. Lab Anim Sci 49: 269-275, 1999.
16. Soga M, Hashimoto S, Kishimoto Y, Hirasawa T, Makino S and Inagaki S: Insulin resistance, steatohepatitis and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep (ob) gene. Exp Anim 59: 407-419, 2010.
17. Sugihara T, Koda M, Kishina M, Kato J, Tokunaga S, Matono T, Ueki M and Murawaki Y: Fatty liver Shionogi ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model. Hepatol Res 43: 547-556, 2013.
18. Jung YA, Choi YK, Jung GS, Seo HY, Kim HS, Jang BK, Kim JG, Lee IK, Kim MK and Park KG: Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract 105: 47-57, 2014.
19. McKnight AJ, Macfarlane AJ, Dri P, Turley L, Willis AC and Gordon S. Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. J Biol Chem 271: 486-489, 1996.
20. Livak KJ and Schmittgen TD. Analysis of relative gene expression data usingreal-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
21. Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52: 1836-1846, 2010.
22. Tessari P, Coracina A, Cosma A and Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19: 291-302, 2009.
23. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
24. Youssef W and McCullough AJ: Diabetes mellitus, obesity and hepatic steatosis. Semin Gastrointest Dis 13: 17-30, 2002.
25. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 16: 651-658, 2006.
26. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE and Taskinen MR: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49: 2049-2057, 2006.
27. Scott R, Loeys T, Davies MJ and Engel SS; Sitagliptin Study 801 Group: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 10: 959-969, 2008.
28. Schreuder TC, Verwer BJ, van Nieuwkerk CM and Mulder CJ: Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 14: 2474-2486, 2008.
29. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, et al: Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246-1257, 2011.
30. Foley JE and Jordan J: Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Vasc Health Risk Manag 6: 541-548, 2010.
31. Foufelle F and Ferre P: New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: A role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 366: 377-391, 2002.
32. Bugianesi E, MuCullough AJ and Marchesini G: Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 42: 987-1000, 2005.
33. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et al: (2R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a) pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141-151, 2005.
34. Wetterau JR, Lin MC and Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1345: 136-150, 1997.
35. Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, Mastrocola R, Novo E, Bertolani C, Milani S, Vizzutti F, et al: Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 46: 230-238, 2007.
36. Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, Schwabe RF and Brenner DA: CCR2 promotes hepatic fibrosis in mice. Hepatology 50: 185-197, 2009.
37. Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W, Vizzutti F, Sutti S, Locatelli I, Navari N, et al: Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond) 123: 459-471, 2012.
38. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A and Avogaro A: The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care 33: 1607-1609, 2010.
39. Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, et al: Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol 49: 481-491, 2013.